Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-08-10 DOI:10.1016/j.clgc.2024.102187
Jennifer Obasi , Komal Sharma , Navonil De Sarkar , Emmanuel S. Antonarakis , Deepak Kilari
{"title":"Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer","authors":"Jennifer Obasi ,&nbsp;Komal Sharma ,&nbsp;Navonil De Sarkar ,&nbsp;Emmanuel S. Antonarakis ,&nbsp;Deepak Kilari","doi":"10.1016/j.clgc.2024.102187","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.</p></span></li><li><span>•</span><span><p>A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.</p></span></li><li><span>•</span><span><p>In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.</p></span></li></ul></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001587","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

  • PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.

  • A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.

  • In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PARP抑制后的铂化疗在HRR缺陷的转移性阉割耐药前列腺癌中的应用
-在这部分患者中,如果 PARP 抑制剂失效后未检测到逆转突变,可考虑使用卡铂进行挽救。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
期刊最新文献
A Systematic Review of Sleep Disturbance in Idiopathic Intracranial Hypertension. Advancing Patient Education in Idiopathic Intracranial Hypertension: The Promise of Large Language Models. Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments. Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey. Association Between LACE+ Index Risk Category and 90-Day Mortality After Stroke.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1